Shelf life (days): 1460.0
Formulation: A crystalline solid
Formal Name: 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-4(3H)-quinazolinone
Purity: ≥98%
Formula Markup: C20H22N2O5
Formula Weight: 370.4
CAS Number: 1044870-39-4
Notes: The bromodomain and extra terminal (BET) proteins interact with acetylated lysine-containing sequences on target proteins via their bromodomains, commonly altering gene transcription.{19044} The human BET proteins contain two bromodomains, the first (BD1) being closer to the N-terminus than the second (BD2). RVX-208 is a selective antagonist of BET bromodomains, binding with 10-100-fold higher affinity for BD2 (IC50 = 0.04-0.28 µM) over BD1 (IC50 = 1.8-3.1 µM).{26809,26810} RVX-208 causes the selective release of BET proteins from chromatin in cells.{26809,26810} It interferes with the BET protein BRD4, resulting in an increased expression of apolipoprotein (Apo) A1 in cells, mice, monkeys, and humans.{26807,26811} RVX-208 also reduces atherosclerosis in hyperlipidemic ApoE-deficient mice.{26811}
English
Deutsch
